TNF-α blockers present a revolutionizing therapeutic choice for inflammatory diseases such as RA, AS, plaque psoriasis, psoriatic arthritis, juvenile polyarticular rheumatoid arthritis, and inflammatory bowel disease (CD and ulcerative colitis). This evidence concerns the gene TNF and rheumatoid arthritis.